Cue Biopharma, Inc. · NASDAQ:CUE
Cue Biopharma — Corporate Update (April 2025)
18 slides from Cue Biopharma's corporate update, Apr 15, 2025
Slide 1: Mobilizing the Patient's Immune System to Treat Serious Diseases
Mobilizing the Patient’s Immune System to Treat Serious Diseases April 15, 2025 ©2025 ©2024 Cue Biopharma C O N F I D E N T I A L D O N O T D I S T R I B U T E 1
Slide 2: Cautionary Note Regarding Forward Looking Statements
Cautionary Note Regarding Forward Looking Statements This presentation and the accompanying oral presentation shall not constitute an offer to sell conditions. Because forward-looking statements relate to the future, they are subject to or the solicitation of an offer to buy any securities, nor shal
Slide 3: Our Mission: To Develop Therapies to Mobilize the Immune System
Our Mission: To Develop Therapies to Mobilize the Immune System ©2025 ©2024 Cue Biopharma C O N F I D E N T I A L D O N O T D I S T R I B U T E 3
Slide 4: Our Solution: Precise Activation and Expansion of Disease Relevant T Cells
Our Solution Precise Activation and Expansion of Disease Relevant T Cells Natural Immune Synapse CUE Immuno-STAT® T Cell Signal 1 Specificity We have engineered our Immuno-STAT platform to T Cell mimic nature’s signals HLA using interchangeable Target Scaffold Signal 2 components Cell Synergy to act
Slide 5: Strategic Collaboration to Accelerate Long Term Value
Strategic Collaboration to Accelerate Long Term Value Focus on Advancing CUE-501 to Maximize Shareholder Value BOEHRINGER INGELHEIM COLLABORATION CUE-501 • Accelerate development • Develop CUE-501, a novel bispecific for B cell depletion • $12 million upfront payment, plus research support payments
Slide 6: Join Us For a Virtual R&D Update Planned for Mid-May 2025
Join Us For a Virtual R&D Update Planned for Mid-May 2025 ©2025 ©2024 Cue Biopharma C O N F I D E N T I A L D O N O T D I S T R I B U T E 6
Slide 7: The CUE-500 Series
The CUE-500 Series Redirecting Abundant Viral T Cells to Eradicate Pathogenic Cells Pathogenic Cell Depletion Using Anti-viral T cells ©2025 ©2024 Cue Biopharma C O N F I D E N T I A L D O N O T D I S T R I B U T E 7
Slide 8: Immune Imbalance Underlies the Pathology in both Cancer and Autoimmune Disease
Immune Imbalance Underlies the Pathology in both Cancer and Autoimmune Disease THE PROBLEM INADEQUATE APPROACHES OUR SOLUTION The immune system fights Broad, Fabrication Selectively Expand and cancer and prevents Indiscriminate of Disease- Activate the Immune System to autoimmune disease Activation
Slide 9: CUE-500 Series Provides a Platform Opportunity for Redirected T Cell Killing
CUE-500 Series Provides a Platform Opportunity for Redirected T Cell Killing Across Multiple Large Market Opportunities THE PROBLEM OUR SOLUTION Depletion of pathogenic cells through non-selective Deplete Target Cells Using Natural & Abundant stimulation of killer T cells leads to high incidence of
Slide 10: CUE-500 Series Redirecting Patients' Existing Anti-Viral Killer T cells
CUE-500 Series Redirecting Patients’ Existing Anti-Viral Killer T cells to Target Cancer and Autoimmune Diseases Potential to Target Multiple Types of Pathogenic Cells • Paints target cell with a virus-specific epitope Targeted Mechanism • Redirects anti-viral killer T cells to eradicate Viral Pepti
Slide 11: CUE-501: B Cell Depletion Designed to Direct Selective Memory T cells
CUE-501: B Cell Depletion Designed to Direct Selective Memory T cells to Deplete B cells to Address Autoimmune and Inflammatory Diseases In Preclinical Studies, CUE-501 Maintains Activity with No Evident Cytokine Release CUE-501 (CMV) CUE-501 appears to kill Vehicle anti- human B cells with efficacy
Slide 12: CUE-500 Series Designed to Provide Superior Differentiation for Target Cell Depletion
CUE-500 Series Designed to Provide Superior Differentiation for Target Cell Depletion CUE-501 T cell Engager (Preclinical) Selective activation of trained virus-specific killer T cells YES (“effector VST cells”) Takes advantage of effector VST cells present in YES circulation and diseased tissue Avo
Slide 13: CUE-500 Series Designed to Provide Superior Differentiation for Target Cell Depletion
CUE-500 Series Designed to Provide Superior Differentiation for Target Cell Depletion Clinical CAR-T Clinical Pan T cell Engagers CUE-501 T cell Engager Cell Therapy (e.g., anti-CD3/CD19) (Preclinical) Selective activation of trained virus-specific killer T NO NO YES cells (“effector VST cells”) Tak
Slide 14: CUE-500 Series Precision Therapeutics Redirect Anti-Viral Killer T Cells
CUE-500 Series Precision Therapeutics Redirect Anti-Viral Killer T Cells to Eradicate Pathogenic Cells CUE-500 SERIES Peptide ScFv HLA B Cell Cancer Fibrosis, etc. Autoimmune / Allergy • CD19 (CUE-501) • CD79 • HER2 • TROP2 • BCMA • CD138 • PSMA • Others • CD20 • CD39 ©2025 ©2024 Cue Biopharma C O N
Slide 15: Strategic Collaboration and License Agreement
Strategic Collaboration and License Agreement ©2025 ©2024 Cue Biopharma C O N F I D E N T I A L D O N O T D I S T R I B U T E 15
Slide 16: CUE-501 Partnering with Boehringer Ingelheim to Accelerate Development
CUE-501 Partnering with Boehringer Ingelheim to Accelerate Development of CUE-501 Upfront $12 million R&D Funding Providing research support payments Up to $345 million in success-based milestone payments, Milestones beginning with two preclinical development milestones, plus and Royalties royalties
Slide 17: Strategic Boehringer Ingelheim Partnership: Acceleration. Validation.
Strategic Boehringer Ingelheim Partnership Acceleration. Validation. ACCELERATING CUE-501 VALIDATING Autoimmune Disease + Cancer Dedicated resources with A strategic fit with the the potential to expansion of Boehringer accelerate the drug Ingelheim’s autoimmune development path, and inflammatory st
Slide 18: Thank you.
Thank you. ©2025 ©2024 Cue Biopharma C O N F I D E N T I A L D O N O T D I S T R I B U T E 18